Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Aston University and pharmaceutical giant sign for medical future of Midlands

11.10.2004


Aston University in Birmingham, UK has just signed a long-term agreement with pharmaceutical manufacturing giant, Mayne Pharma Plc , to run the first dedicated medical manufacturing clean room in the region.



The room will be used to produce specialist cancer and other drugs and make them available across the Midlands. This will address the particular need in the region for aseptic facilities to support the preparation of pharmaceuticals with a short shelf life - particularly in the treatment of children. In addition to this, the agreement - which was facilitated by Aston University’s Business Partnership Unit – will also create a unique opportunity for the West Midlands.

Guppy Dhariwal, Director of Finance and Business Services at Aston stated: “Aston University is delighted to be entering into this exciting new partnership. It will not only create new jobs in the region but it will, to the best of our knowledge, be the first manufacturing unit of its type that brings together high-quality university research with advanced pharmaceutical manufacturing techniques.”


The alliance will offer Aston University (which boasts the only pharmacy school in the region) and Mayne Pharma numerous collaborative opportunities, and will contribute directly to the University’s research and teaching in pharmacy.

John Edwards Chief Executive of Advantage West Midlands said: “Medical technologies is a growth industry in this region and we’re delighted to support Aston University in this exciting venture.”

The clean room provides an ultra clean, sterile and controlled environment for pharmaceutical manufacture, research and teaching and will offer a complete specialist environment to support the development of new medicines. Its rooms are temperature and humidity controlled to allow the aseptic production, manipulation and reconstitution of a variety of medical products (including chemotherapy drugs usually used in the treatment of cancer and individually tailored treatments for premature babies) that cannot be sterilised commercially.

Scott Richards, President, Mayne Pharma EMEA, said: “This is an important development for growing Mayne’s aseptic manufacturing business operations in the UK. Being located at such a research-focussed university as Aston in Birmingham, and so close to excellent transport links will enable us to offer outstanding levels of service for our customers in the Midlands whilst also supporting our wider UK business.”

Paul Burkwood | alfa
Further information:
http://www.aston.ac.uk

More articles from Life Sciences:

nachricht New technology offers fast peptide synthesis
28.02.2017 | Massachusetts Institute of Technology

nachricht Biofuel produced by microalgae
28.02.2017 | Tokyo Institute of Technology

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Safe glide at total engine failure with ELA-inside

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded after a glide flight with an Airbus A320 in ditching on the Hudson River. All 155 people on board were saved.

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded...

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

New technology offers fast peptide synthesis

28.02.2017 | Life Sciences

WSU research advances energy savings for oil, gas industries

28.02.2017 | Power and Electrical Engineering

Who can find the fish that makes the best sound?

28.02.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>